Figure 1

Cumulative proportion of infected trial participants for an infection-blocking vaccine with an average individual efficacy of 45.0% based on RTS,S, and in a similar setting to the Mozambique trial site described by Alonso et al[5]. (A) Cumulative proportion of unvaccinated trial participants infected under a range of transmission heterogeneities. (B) Cumulative proportion of vaccinated trial participants infected for a range of vaccine types. The proportion infected for an all-or-nothing vaccine can never cross the dashed line marked 1-V = 0.55 as the 45% of vaccinees with total protection will never become infected. Note that the 4 vaccines each have the same individual efficacy but different heterogeneities in vaccine efficacy.